Price T Rowe Associates Inc. MD Has $89.85 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Price T Rowe Associates Inc. MD grew its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 14.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,364,392 shares of the company's stock after buying an additional 685,371 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 4.07% of Centessa Pharmaceuticals worth $89,854,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in CNTA. GAMMA Investing LLC lifted its position in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after buying an additional 5,316 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Centessa Pharmaceuticals by 122.9% in the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after buying an additional 12,506 shares during the period. Finally, State Street Corp bought a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $777,000. 82.01% of the stock is owned by institutional investors.

Insider Activity at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the completion of the transaction, the chief executive officer now directly owns 331,017 shares of the company's stock, valued at $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $13.61, for a total value of $159,808.62. Following the transaction, the insider now owns 122,279 shares of the company's stock, valued at approximately $1,664,217.19. The trade was a 8.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 219,824 shares of company stock valued at $3,581,039. 11.59% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on CNTA. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating for the company. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target for the company. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Trading Up 0.8 %

Shares of Centessa Pharmaceuticals stock traded up $0.11 during trading hours on Friday, hitting $13.61. The company's stock had a trading volume of 749,858 shares, compared to its average volume of 616,431. The company has a market capitalization of $1.81 billion, a PE ratio of -8.90 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a 50 day moving average of $14.17 and a 200 day moving average of $15.78. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. Analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.